Fig. 2

High NSMCE2 and MAL2 RNA expression in tumors is linked to breast cancer patients’ poor prognosis. A Box plots showing that gene expression levels are significantly higher in breast tumor samples when compared to normal samples for 9 SE-associated genes. Expression levels information for normal samples (Normal Tissue GTEX and Solid Tissue Normal TCGA) was obtained from GTEX and TCGA RNA-Seq datasets, respectively. Expression levels from primary breast tumors (Primary Tumor TCGA) were obtained from TCGA RNA-Seq datasets. Gene expression levels were compared by ANOVA. B Univariate Kaplan–Meier plots showing breast cancer patients' survival probability over time based on gene expression for each NSMCE2, MAL2, or EIF3H. These analyses were performed using breast primary tumors RNA-Seq data mined from two independent datasets, TCGA (n = 1097) or METABRIC (n = 1904). Red and blue curves represent samples that show high and low gene expression levels, respectively, relative to the median expression value for each gene. High levels of either NSMCE2 or MAL2 were found to be significantly correlated with breast cancer patients' poor prognosis in the two datasets. Plots were analyzed using the Log-rank test. OS = overall survival, RFS = relapse free survival. C Multivariate Cox model of overall survival for NSMCE2 and MAL2 RNA expression in TCGA breast primary tumors including age, stage and tumor subtype as covariates show that high levels of either NSMCE2 or MAL2 are significantly correlated with patients' poor prognosis